Skip to main content

Table 1 Clinical characteristics of study patients

From: Risk of hypoglycemia associated with repaglinide combined with clopidogrel, a retrospective cohort study

Characteristics

Repaglinide and clopidogrel group

Mitiglinide and clopidogrel group

Repaglinide group

p value

(N = 15)

(N = 15)

(N = 15)

Age

75.6 ± 12.2

70.4 ± 11.5

76.1 ± 10.9

0.332*

Male (%)

10 (66.7%)

12 (80.0%)

10 (66.7%)

0.649***

BMI

23.6 ± 3.2

24.4 ± 2.9

23.2 ± 3.9

0.598*

HbA1c

9.3 ± 2.0

9.5 ± 2.0

9.7 ± 2.6

0.851*

Serum creatinine

0.84 ± 0.32

0.80 ± 0.16

0.76 ± 0.16

0.594*

Liver function (Grade 1 [CTCAE ver.4.0]: AST, ALT, or T-Bil)

4 (26.7%)

5 (33.3%)

3 (20.0%)

0.912**

Calorie intake (kcal)

1325.9 ± 283.3

1497.0 ± 247.5

1517.2 ± 168.7

0.065*

Concomitant agent use (oral hypoglycemic drugs, insulin, GLP-1 agonists, and/or agents which may enhance the hypoglycemic action of repaglinide or mitiglinide, other than the above)

10 (67.7%)

9 (60.0%)

9 (60.0%)

0.910***

  1. Mean ± S.D., * One-way analysis of variance, ** Fisher’s exact test, *** Chi-square test